U.S. markets closed
  • S&P Futures

    3,887.75
    -11.00 (-0.28%)
     
  • Dow Futures

    31,419.00
    -90.00 (-0.29%)
     
  • Nasdaq Futures

    13,260.25
    -19.50 (-0.15%)
     
  • Russell 2000 Futures

    2,264.90
    -9.90 (-0.44%)
     
  • Crude Oil

    59.64
    -1.00 (-1.65%)
     
  • Gold

    1,710.10
    -12.90 (-0.75%)
     
  • Silver

    26.17
    -0.51 (-1.92%)
     
  • EUR/USD

    1.2024
    -0.0036 (-0.30%)
     
  • 10-Yr Bond

    1.4460
    -0.0140 (-0.96%)
     
  • Vix

    23.35
    -4.60 (-16.46%)
     
  • GBP/USD

    1.3883
    -0.0038 (-0.27%)
     
  • USD/JPY

    106.7480
    +0.0180 (+0.02%)
     
  • BTC-USD

    49,341.28
    +3,099.69 (+6.70%)
     
  • CMC Crypto 200

    989.31
    +61.08 (+6.58%)
     
  • FTSE 100

    6,588.53
    +105.10 (+1.62%)
     
  • Nikkei 225

    29,554.75
    -108.75 (-0.37%)
     

Optinose to Present at the 2019 Cantor Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

YARDLEY, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the 2019 Cantor Global Healthcare Conference on October 2, 2019, at 11:15 a.m. ET.

To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website.

A replay of the webcast will be available for 30 days following the conclusion of the event.

About Optinose
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has offices in the U.S., the U.K. and Norway. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531